EyeWorld Asia-Pacific December 2014 Issue

December 2014 45 EWAP GLAUCOMA use marijuana (presented as a poster at the American Glaucoma Society annual meeting in March 2014). Clinical implications The current landscape of innovation in glaucoma therapy is encouraging and may well produce approved products that will enable us all to better care for our patients and preserve their visual function. Prostaglandins have set the bar very high for a paradigm shift in first-line therapy, but the adjunctive market remains wide open. Perhaps one of these new agents will meet the unmet need for an effective adjunct to the prostaglandin class. Another area of unmet need is in the arena of drug delivery. Developing a drug or drug delivery system that obviates the need for daily topical therapy would be paradigm-changing. It can be done—as evidenced by steroid implants, intravitreal injections of vascular endothelial growth factor inhibitors, and even the ancient pilocarpine Ocusert. A number of promising technologies are in various stages of investigation. With luck and persistence, one or more of these may come to fruition. EWAP Editors’ note: Dr. Kaufman has financial interests with Bausch + Lomb and other ophthalmic companies. Drs. Belyea and Jampel have no financial interests related to this article. Contact information Belyea: dbelyea@mfa.gwu.edu Jampel: hjampel@jhmi.edu Kaufman: kaufmanp@mhub.ophth.wisc.edu 2014 APACRS Film Festival Winning Videos FF1: Cataract / Implant Surgery FF2: Cataract Complications / Challenging Cases FF3: Cornea / Refractive Surgery FF4: General Interest APACRS Secretariat Singapore c/o Singapore National Eye Centre 11 Third Hospital Avenue, Singapore 168751 Contact: apacrs@apacrs.org • www.apacrs.org